Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Incidence, patterns, and outcomes of adenovirus infections in patients following allogeneic hematopoietic cell transplantation

Areeba Ismail, Amna Bint I Munir, Fatima Imran et al. Nov 03, 2025 pp. 7733-7733 10.1182/blood-2025-7733

Abstract Background: Adenovirus (AdV) infection is a recognized complication following allogeneic hematopoietic cell tra...

The exact system for precision clinical trial matching: Case study of accuracy with follicular lymphoma trials

Adam Blum, Jessica Okosun, Samar Elkassas et al. Nov 03, 2025 pp. 6185-6185 10.1182/blood-2025-6185

Abstract Introduction: Accurate clinical trial matching remains a major barrier to oncology trial enrollment, particularly due to the diffic...

Neutrophil count is an independent prognostic indicator in early T-cell precursor lymphoblastic leukemia

Jieping Lin, Xiaoyuan Gong, Nanfang Zhuo et al. Nov 03, 2025 pp. 6892-6892 10.1182/blood-2025-6892

Abstract Purpose Early T-cell precursor lymphoblastic leukemia (ETP-ALL) is an immunophenotypically defined subgroup of T-ALL associated wit...

A Phase 1 study of KITE-753 or KITE-363 in patients with relapsed/refractory B-cell lymphoma: Initial safety and preliminary efficacy of KITE-753 and updated results of KITE-363

Saurabh Dahiya, Matthew Ulrickson, Jean Yared et al. Nov 03, 2025 pp. 265-265 10.1182/blood-2025-265

Abstract Introduction: KITE-363 and KITE-753 are dual-targeting, autologous chimeric antigen receptor (CAR) T-cell therapies designed to ove...

Trends and disparities in alzheimer's disease and anemia-related mortality in adults aged ≥ 65 years in the United States from 1999 to 2023: A CDC wonder database analysis

Anas nasir, Muhammad Ali, Ahmed Raza et al. Nov 03, 2025 pp. 8002-8002 10.1182/blood-2025-8002

Abstract Introduction: Alzheimer's disease and anemia are both common among older adults in the United States and are linked to increased mo...

Epcoritamab monotherapy provides superior efficacy vs non–anthracycline-containing regimens in newly diagnosed elderly DLBCL patients deemed unsuitable for anthracycline-containing regimens: A match-adjusted comparative efficacy analysis

Patrick Connor Johnson, Evelyn Guo, Guihua Zhang et al. Nov 03, 2025 pp. 7251-7251 10.1182/blood-2025-7251

Abstract Introduction: Newly diagnosed diffuse large B-cell (DLBCL) patients (pts) who are older and/or have specific comorbidities may be u...

The role of palliative care in the multidisciplinary treatment of immunoglobulin light chain amyloidosis

Pedro Vianna, Joshua Lakin, Samantha Gelfand et al. Nov 03, 2025 pp. 8152-8152 10.1182/blood-2025-8152

Abstract Background: Immunoglobulin light chain (AL) amyloidosis is a plasma cell neoplasm characterized by deposition of intrinsically unst...

Impact of geographic distance and residential setting on overall survival in patients with Acute Myeloid Leukemia

Warner Thomas, Sunpil Hwang, Sidharth Mahajan et al. Nov 03, 2025 pp. 8194-8194 10.1182/blood-2025-8194

Abstract Background: The treatment of acute myeloid leukemia (AML), particularly in the initial (induction) phase, is ty...

Prediction model for pediatric return visits for sickle cell disease post-emergency department discharge for acute pain

Keli Coleman, Amanda Brandow, Amy Drendel et al. Nov 03, 2025 pp. 1169-1169 10.1182/blood-2025-1169

Abstract Introduction: Greater than one in four children with sickle cell disease (SCD) treated for pain in the emergency department (ED) re...

Real-world outcomes of mosunetuzumab use in indolent and aggressive lymphomas

Andrew Jallouk, Lorenzo Falchi, Ayushi Chauhan et al. Nov 03, 2025 pp. 4515-4515 10.1182/blood-2025-4515

Abstract Introduction Mosunetuzumab (mosun) is a CD20xCD3 bispecific antibody approved as a single agent for treatment of follicular lymphom...

Osteonecrosis risk in adult ALL: Insights from real-world clinical laboratory data in eighty-seven patients treated with peg-asparaginase

Felix Klingler, Nicola Gökbuget, Carsten Bokemeyer et al. Nov 03, 2025 pp. 3322-3322 10.1182/blood-2025-3322

Abstract Acute lymphoblastic leukemia (ALL) is a potentially fatal disease treated with intensive multi-agent therapy. In Germany, treatment...

A phase II study of lenalidomide, zanubrutinib plus obinutuzumab in patients with FLIPI2 high-risk newly diagnosed follicular lymphoma: An interim analysis

Li Wang, Zhong Zheng, Ruichi Li et al. Nov 03, 2025 pp. 7123-7123 10.1182/blood-2025-7123

Abstract Background Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma. Although rituximab plus l...

Red-lilly app: A digital tool for the evaluation of menstrual bleeding patterns to support the early detection of bleeding disorders in women

Susan Halimeh, Ayman Daoud, Evangelia Antoniou Nov 03, 2025 pp. 4862-4862 10.1182/blood-2025-4862

Abstract Background: According to the World Health Organization, approximately 18 million women are affected by heavy me...

Tocilizumab prophylaxis in patients receiving CAR-T cell immunotherapy for hematological malignancies: A systematic review and meta-analysis

Maria Gavriilaki, Paschalis Evangelidis, Nikolaos Evangelidis et al. Nov 03, 2025 pp. 7668-7668 10.1182/blood-2025-7668

Abstract Background: Chimeric antigen receptor-T (CAR-T) cell immunotherapy has revolutionized the therapeutic landscape for patients with r...

Integrated analysis of mogamulizumab trials for mature T-cell lymphomas, investigating differences in longitudinal effects between responders and non-responders

Nobuaki Nakano, Kenta Murotani, Yoshito Ohya et al. Nov 03, 2025 pp. 1867-1867 10.1182/blood-2025-1867

Abstract Introduction: Mogamulizumab (moga), an anti-CC chemokine receptor 4 (CCR4) antibody, is approved in Japan for CCR4+ adult T-cell le...

Characterisation of the megakaryocyte proteome in patients with Philadelphia negative myeloproliferative neoplasms

Indu Raman, Cavan Bennett, Anne Pettikiriarachchi et al. Nov 03, 2025 pp. 5539-5539 10.1182/blood-2025-5539

Abstract Introduction: Megakaryocytes are considered to drive pathology in the classical Philadelphia-negative myeloproliferative neoplasms...

Trends and disparities in premature mortality from hematologic malignancies: Analysis of CDC wonder data, 1999-2020

Jowan Al-Nusair, Mohammed Al-Nusair, Kara Piechowski et al. Nov 03, 2025 pp. 8086-8086 10.1182/blood-2025-8086

Abstract Background: Premature mortality from hematologic malignancies represents a major source of life-years lost, and trends and disparit...

Ponatinib-based combination therapies including asciminib and venetoclax were effective on patient-derived xenograft models of chronic myeloid leukemia in blast Phase

Adam Laznicka, Nikola Curik, Jitka Krizkova et al. Nov 03, 2025 pp. 3284-3284 10.1182/blood-2025-3284

Abstract Introduction:Blast phase of chronic myeloid leukemia (CML-BP) represents advanced and aggressive phase of CML, marked by high genet...

Venetoclax retreatment of real-world patients with chronic lymphocytic leukemia previously treated with venetoclax-based regimens

Mazyar Shadman, Meghan Thompson, Nilanjan Ghosh et al. Nov 03, 2025 pp. 2108-2108 10.1182/blood-2025-2108

Abstract BACKGROUND Venetoclax (Ven) has notable therapeutic potential in the treatment of chronic lymphocytic leukemia (CLL). As a result of...

Sonar-AI discovers first comprehensively described cases of GLP-1 receptor agonist associated thrombocytopenia: Faster, cheaper, and better than the 20th century approach of RADAR/sonar

Mia Lynch, Samuel Ruder, James Bussel et al. Nov 03, 2025 pp. 6581-6581 10.1182/blood-2025-6581

Abstract Background/Introduction. The 21st century Southern Network on Adverse Reactions-Artificial Intelligence (SONAR-AI) is a team of mul...

Lysyl oxidases directly control cell surface abundance of platelet-derived growth factor receptors and signaling in osteoblasts

Wolfgang Jarolimek, Jessica Stolp, Lara Perryman et al. Nov 03, 2025 pp. 1406-1406 10.1182/blood-2025-1406

Abstract Introduction Platelet-derived Growth Factor Receptors α and β (PDGFRs) are fundamental regulators of cell devel...

Standardizing VTE prophylaxis in the inpatient setting: A quality improvement project

Devang Namjoshi, Sharanya Tripathi, Panah Parab et al. Nov 03, 2025 pp. 2620-2620 10.1182/blood-2025-2620

Abstract Introduction: Venous thromboembolism (VTE) is a major preventable cause of morbidity and mortality in hospitalized patients. Pharma...

Efficacy and safety of iptacopan in paroxysmal nocturnal hemoglobinuria (PNH): A real-world study of 35 patients from anhui, China

Ziwei Zhou, Fengbo Jin, Li Ye et al. Nov 03, 2025 pp. 6538-6538 10.1182/blood-2025-6538

Abstract Efficacy and Safety of Iptacopan in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Multidimensional Analysis of 35 Patients Objective...

Etoposide +cytarabine plus G-CSF mitigates daratumumab-associated impairment on stem cell mobilization yields in multiple myeloma

Zhijuan Zhu, Xiaofan Li, Nainong Li Nov 03, 2025 pp. 7694-7694 10.1182/blood-2025-7694

Abstract Objective: Quadruplet induction therapy comprising daratumumab(dara) and lenalidomide(lena), followed by high-dose chemotherapy and...

Fusion-specific regulation of polyamine synthesis sensitizes to BCL-XL inhibition in TCF3::PBX1+ B-ALL

James Kim, Sarah Cherkaoui, Simona Ulrich et al. Nov 03, 2025 pp. 3260-3260 10.1182/blood-2025-3260

Abstract Fusion transcription factors (TF) are hallmark oncogenic drivers in pediatric B cell acute lymphoblastic leukemia (B-ALL), contribu...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page